Randox has launched its new Evidence RABTA (Random Access Biochip Technology Analyser), which the firm says sets a new standard in laboratory diagnostics.
The new addition to the Evidence series range of analysers, this state-of-the-art analyser combines advanced Biochip Array Technology with exceptional efficiency, designed to meet the demanding needs of modern laboratories.
Capable of processing up to 60 samples per hour, delivering up to 2,640 test results per hour, and an impressive 19,580 test results per day, the RABTA analyser offers seamless random-access capabilities, designed to perform multiple tests on various samples, eliminating the constraints of batch testing.
The analyser’s advanced software allows users to assign samples as priority, ensuring rapid processing and reporting of critical results. The time to first result is just 36 minutes, with remaining results released one sample per minute onward. RABTA software intuitively analyses what tests are being run and assigns the order of samples in the most time-efficient way.
Utilising single-use tips for aspiration and dispensing, the RABTA ensures no carry-over risk, maintaining high accuracy with every result. The innovative Biochip Array Technology enables the simultaneous detection of up to 44 targets from a single patient sample, reducing time and resources needed for diagnostics.
The RABTA analyser features five intuitive modules tailored for specific functions, ensuring easy integration and adaptability for various applications, from diagnostics to advanced research. The modules include reagent, biochip, signal, tip, and sample storage, all designed to maximise efficiency and ensure seamless operation.